Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study - Wikidata - wikimedia - TriplyDB

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

http://www.wikidata.org/entity/Q36404761

about

Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016 Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma Comparison of hepatocellular carcinoma in Eastern versus Western populations.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity.Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: a case-control study.Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling.The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis.GIT1 is a novel prognostic biomarker and facilitates tumor progression via activating ERK/MMP9 signaling in hepatocellular carcinoma Arenobufagin intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR pathway.Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells.A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis.The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE.All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments.Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ.Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database.Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.Global trends in the burden of liver cancer.Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients.LI-RADS and transplantation for hepatocellular carcinoma.Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma.A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score.Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy.New players in non-alcoholic fatty liver disease induced carcinogenesis: lipid dysregulation impairs liver immune surveillance.

P2860

Q26743666-89854591-A168-4C0F-BC5A-E7FBBD243B0D Q26752478-158A7D5F-87C3-4754-8A37-FB206EF34703 Q26767217-7A4954CD-0BE6-4C26-AA8A-DEC688274733 Q28080175-CAA4F7D2-5B3B-40D1-BD68-76EF1038BA1F Q30245396-41AA0407-069A-4D5D-B0A1-B4F1CE35F73A Q30250096-29BB9C46-37C8-4776-8CF0-C6DB6F0548D7 Q33572657-CEC9377F-EAB0-47CE-A765-276A307938B8 Q33648616-B9635302-E810-4932-B1C8-32C2B569AAC6 Q33677461-B64E9810-604B-446D-8B7B-DFEA34207B5B Q33677699-359B0CE3-A753-4B31-87BF-271CF859F78F Q36000994-288C187A-6547-48C5-9A3F-2603BBD9223D Q36251812-D30F0F7E-62F1-4B71-8739-8F1C5E6D6DCB Q36262680-E21BF0E7-15A9-4BD8-9F24-61A578E8D990 Q36329899-C4B749BE-B83E-430C-9CF8-E789A54F20A0 Q36399068-8C45AB26-4CE5-459D-9D4B-54AE5CE5C3C4 Q36544066-8E38404C-138A-4B84-8FD1-05B149919C79 Q36598514-24C756B5-FF78-4B8F-A5EF-37288D2F9293 Q36656417-F1595BD5-AE10-419D-8209-2AC76C02170C Q37362644-56EA214C-B1B4-4E4A-BADD-E795BAC5720C Q37367485-4BBD8F09-7A62-499D-86C2-CD5A4379526C Q37684567-07951F45-94C4-43FB-BF7E-728BDCB45871 Q37738796-B9DA55FC-7CD7-4705-93EB-A03058883DA8 Q38400804-13247B0A-7EF0-47B4-8118-729B083E613B Q38416627-C1F80216-917F-439F-9044-3895F1BB9E67 Q38608806-0AC1147A-5ED4-4727-AF7A-C9B8711C5F8A Q38635611-5E4CD5AF-FCB8-48C3-AAF5-92C90A108039 Q38660714-A5AFCD2A-5588-4A99-AE40-41B084148B5F Q38688473-ACEAB254-2D5F-4D8D-BF0D-80D112553DFD Q38725757-D6251CAA-91F1-45F6-9E5A-B8EFD0CE4AA2 Q38739412-38A82BD6-EC6D-4AA9-8361-1DBAE78B8F68 Q38820543-27FCC4C1-3693-4FE5-B477-86654BA1B42C Q39173460-3A91E423-D560-4818-AFAE-4FC0953A5827 Q39212821-6EDFB061-EE38-4C4C-9311-A72F9C428491 Q39371292-618B0841-F163-4642-9D12-4673B44EBEE8 Q39434012-8D85D577-656A-49C1-959B-1A935CC7AD5F Q39494954-7F595CAD-5734-4040-A5F8-4DF0FAC2339A Q40084423-CA3BC823-9B0E-4892-AF17-83F9F88BDDCB Q40091767-DBAB9BC6-C3F7-484F-B8B7-0C218CBFF693 Q40149527-F7CD0F45-D764-474C-8E76-2570CEDE3937 Q40357772-8B56CF96-8DEF-4F36-B71E-AFF2F766C853

P2860

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

http://www.wikidata.org/entity/Q36404761

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Global patterns of hepatocellu ...... sis to death: the BRIDGE Study

@ast

Global patterns of hepatocellu ...... sis to death: the BRIDGE Study

@en

type

label

Global patterns of hepatocellu ...... sis to death: the BRIDGE Study

@ast

Global patterns of hepatocellu ...... sis to death: the BRIDGE Study

@en

prefLabel

Global patterns of hepatocellu ...... sis to death: the BRIDGE Study

@ast

Global patterns of hepatocellu ...... sis to death: the BRIDGE Study

@en

P1433

Q36404761-1133AD6F-984B-49C1-9E25-AAF5AF73CB38

P1476

Q36404761-56A3568C-0A66-4EA7-AF06-ADAF0F0ABC5E

P2093

Q36404761-006A671B-6833-4B3B-BAB0-3CD591D82308

Q36404761-2C02EE42-79F9-4083-A91C-1CF623F08685

Q36404761-7FECF31A-A506-499F-8866-03C0AD731625

Q36404761-9049B85A-0BF5-4CEF-A9C8-CB5EEBF94615

Q36404761-C6B852A1-DE54-4765-9432-DFE2A32AD322

Q36404761-E8F56708-29E9-4F50-B788-5DA18A315C8E

Q36404761-EC594AA3-DE5C-4001-83E7-D504D7F2715A

Q36404761-ED3815A9-F328-4DB6-A6B4-B146E20E3906

P2860

Q36404761-030E6BB2-8452-4E7A-846F-9A92C56D004D

Q36404761-03546D27-B866-49C7-A8ED-4708995486B9

Q36404761-072D02FC-81DB-4A12-BE94-EB4EB5B6C4D1

Q36404761-0F1CA0EF-1A29-4929-8C06-8C38909C6C48

Q36404761-10BAD7C5-C457-4632-9746-FCDC62091712

Q36404761-17019C85-3118-44B9-AB57-08B138E79234

Q36404761-19B187C0-F947-4FC1-9CEF-375398D12647

Q36404761-1FB504BB-BB02-4934-A676-6C1D9F23492E

Q36404761-32C50C14-D065-4D5A-81B9-F178F3678574

Q36404761-354C78E6-DA42-4CDE-AB97-2A4CA55CD3CA

P304

Q36404761-BB3312CC-7563-4F02-AD39-34F861E2F2FE

P31

Q36404761-92E0FC9B-5DBE-42C7-BB7C-2DFBF3961FEA

P356

Q36404761-114EDF7A-FE90-43E0-A7FC-D16A68322FE5

P433

Q36404761-9F355EE7-95CC-4A28-839A-30321F52C1A1

P478

Q36404761-3681B3F2-F2BE-4808-BCC5-DB63549F5C92

P50

Q36404761-24456131-0FAD-45E1-BE06-9DAF2C25D5EF

Q36404761-926596B0-A643-4975-B354-8F3169739EC1

Q36404761-B48E0A6E-867A-4488-9491-21488F8A8222

P577

Q36404761-8D2A08C2-6CCE-4493-818B-FD5314E3850D

P698

Q36404761-F356EC37-B8FE-403F-BB1E-2DE124F17BCF

P932

Q36404761-5BBFFDBE-C143-4C15-8F4A-493B1E09AB43

P356

P1433

Liver International

P1476

Global patterns of hepatocellu ...... sis to death: the BRIDGE Study

@en

P2093

Joong-Won Park

http://www.w3.org/2001/XMLSchema#string

Lucinda S Orsini

http://www.w3.org/2001/XMLSchema#string

Massimo Colombo

http://www.w3.org/2001/XMLSchema#string

Minshan Chen

http://www.w3.org/2001/XMLSchema#string

Morris Sherman

http://www.w3.org/2001/XMLSchema#string

Myron Schwartz

http://www.w3.org/2001/XMLSchema#string

Philip Johnson

http://www.w3.org/2001/XMLSchema#string

Samuel Wagner

http://www.w3.org/2001/XMLSchema#string

P2860

Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors

Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china

Management of hepatocellular carcinoma: An update

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Epidemiology of viral hepatitis and hepatocellular carcinoma

Toxicity and response criteria of the Eastern Cooperative Oncology Group

P304

2155-2166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.12818

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Lewis R. Roberts

P577

2015-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25752327

http://www.w3.org/2001/XMLSchema#string

P932

4691343

http://www.w3.org/2001/XMLSchema#string